Dr Said Khelwatty
Faculties, deparments and locations
- Faculty of Health, Science, Social Care and Education
- Department of Biomolecular Sciences
- School of Life Sciences, Pharmacy and Chemistry
- Penrhyn Road
Senior Lecturer in Clinical Immunology
- Email:
- s.khelwatty@kingston.ac.uk
About
I began my higher education at Kingston University in 2005 with an undergraduate degree in Biomedical Sciences. Upon graduating in 2008, I undertook a MSc degree in Biomedical Sciences, specialising in Haematology. Subsequently, I started my PhD in Cancer biology and therapeutics in (2009-2012) at Kingston University.
In 2013, I began my tenure as a Postdoctoral Fellow and have worked on several research projects in translational cancer research field, which focuses on finding predictive biomarkers for targeted therapy of colorectal cancer patients and was externally funded by BRIGHT charity, and as a result was also able to gain the fellowship of the Institute of Biomedical Sciences.
I was appointed to a lectureship within the School of Life Science, Pharmacy and Chemistry at Kingston University in 2018. I currently teach on a range of bioscience programmes and very much research active with a focus on colorectal cancer diagnosis and therapy.
Qualifications
- Fellow of Advance Higher Education (FHEA), 2020
- Fellow Institute of Biomedical Science (FIBMS), 2015
- PhD Cancer Biology and Therapeutics, 2012
- MSc Biomedical Sciences, 2009
- BSc (Hons) Biomedical Sciences, 2008
Domains
Module Leader
LS7001 - Research Techniques & Scientific Communication
LS7010 - MSc Research Project Module
Courses taught
I have an extensive research background with particular expertise in translational cancer research. I draw strong technical and analytical expertise in biological and clinical significance of growth factor receptor family with tyrosine kinase activity and cancer stem cells in human malignancies, in particular colorectal cancer.
Currently my research interests are in the following areas:
1. Biological and clinical significance and targeting of growth factor receptors with tyrosine kinase activities in human cancers.
2. Predictive biomarkers for response to therapy in colorectal cancer.
3. Development of monoclonal antibody (mAb) products for use in colorectal cancer diagnosis and therapy
Specialisms
- Cell Culture
- Histopathology
- Molecular Diagnostics
- Drug Resistance Development
- Monoclonal Antibodies
Scholarly affiliations
- British Association for Cancer Research
- American Association for Cancer Research
Publications
Expression of EGFRvIII and its co‑expression with wild‑type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma
Sherif, Ozlem, Khelwatty, Said, Bagwan, Izhar, Seddon, Alan, Dalgleish, Angus, Mudan, Satvinder and Modjtahedi, Helmout, 2024, Oncology Reports (52), 6, pp 172
The combination of afatinib with dasatinib or miransertib results in synergistic growth inhibition of stomach cancer cells
Al-Janaby, Tina, Nahi, Narmin, Seddon, Alan, Bagwan, Izhar, Khelwatty, Said and Modjtahedi, Helmout, 2024, World Journal of Oncology (15), 2, pp 192-208
The co-expression of HER family members and CD109 is common in pancreatic cancer
Khan, Tanzeel, Seddon, Alan, Khelwatty, Said, Dalgleish, Angus, Bagwan, Izhar, Mudan, Satvinder and Modjtahedi, Helmout, 2023, Medical Research Archives (11), 11
HER2 expression is predictive of survival in cetuximab treated patients with RAS wild type metastatic colorectal cancer
Khelwatty, Said A., Puvanenthiran, Soozana, Essapen, Sharadah, Bagwan, Izhar, Seddon, Alan M. and Modjtahedi, Helmout, 2021, Cancers (13), 4, pp e638
Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations : implications for future clinical trials in pancreatic cancer
Khan, Tanzeel, Seddon, Alan M., Dalgleish, Angus G., Khelwatty, Said, Ioannou, Nikolaos, Mudan, Satvinder and Modjtahedi, Helmout, 2020, Oncology Reports (44), 6, pp 2581-2594
Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer
Khelwatty, Said Abdullah, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan M. and Modjtahedi, Helmout, 2019, Oncotarget (10), 18, pp 1704-1715
Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer
Puvanenthiran, S., Essapen, S., Haagsma, B., Bagwan, I., Green, M., Khelwatty, S. A., Seddon, A. M. and Modjtahedi, H., 2018, Oncotarget (9), pp 19662-19674
The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer
Khelwatty, Said, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan and Modjtahedi, Helmout, 2016, Oncotarget (8), 5, pp 7666-7677
Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
Khelwatty, Said A., Essapen, Sharadah, Seddon, Alan M., Fan, Zhen and Modjtahedi, Helmout, 2015, British Journal of Cancer (113), 7, pp 1010-1019
Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival.
Khelwatty, Said Abdullah, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan and Modjtahedi, Helmout, 2014, PloS one (9), 3, pp e91139
Prognostic significance and targeting of HER family in colorectal cancer
Khelwatty, Said Abdullah, Essapen, Sharadah, Seddon, Alan Michael and Modjtahedi, Helmout, 2013, Frontiers in Bioscience (18), 2, pp 394-421
Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10
Modjtahedi, H., Khelwatty, S.A., Kirk, R.S., Seddon, A.M., Essapen, S., Del Vecchio, C.A., Wong, A.J. and Eccles, S., 2012, British Journal of Cancer (106), pp 883-888
Acquired resistance to anti-EGFR mAb ICR62 or afatinib is accompanied by upregulation of the EGFR in colorectal cancer
Khelwatty, Said Abdullah, Essapen, Sharadah, Seddon, Alan M., Fan, Zhen and Modjtahedi, Helmout(2013). In: 104th Annual Meeting of the American Association for Cancer Research, 6-10 Apr 2013 :Washington, U.S.A.
The biological and clinical significance of HER family members and cancer stem cells in colorectal cancer and response to therapeutic interventions
Khelwatty, Said Abdullah (2012), PhD thesis, Kingston University